Systems and records
What was given up, by whom, until when: a supply disruption tradeoff dataset
By SourceX Editorial · Reviewed by Noah Loul ·
8 sections
Short answer
A supply disruption tradeoff dataset records decisions where every feasible response broke at least one requirement. Each episode keeps the options still open on the decision date, the rule each would break, the option chosen, what it gave up, the compensating control, who accepted the risk, when the deviation ends and whether supply returned to normal. FDA's 2022 infant formula policy shows the shape: conditional, case by case, dated to expire.
System export
Given up
Key takeaways
- A tradeoff episode starts where substitution ends: no option on offer meets every requirement, so the record must show which one gave way.
- State each give-up in the requirement's own units and pair it with a compensating control and a named owner.
- Every deviation needs an end date or end condition at the start; FDA's 2022 formula policy ran 182 days, then hinged on a letter of intent.
- Approval often follows urgent action, so keep the acceptance timing as its own label instead of treating silence as consent.
- Score the decision and the outcome separately, and test each episode for a compliant option that was missed.
What belongs in a supply disruption tradeoff dataset?
It belongs to decisions where no available response met every requirement, so someone chose which requirement to give up, for how long and under what safeguard. Each episode should keep the options still feasible on the decision date, the requirement each would break, the option chosen, what it gave up, the compensating control, who accepted the risk, when the exception ends, and whether supply went back to normal afterwards.
Three neighboring records answer different questions. Qualifying a substitute asks whether a new part or supplier meets the requirement; in a tradeoff episode, by construction, nothing on offer does. A late-shipment record asks how one delay was handled; here waiting is only one option, judged against the others. A stakeholder-conflict record settles whose requirement yields in an ordinary purchase; here an outside event has removed the normal supply, and the relaxation is meant to be temporary.
The AI use is direct. An agent asked to keep a production line or a pharmacy supplied through a shortage has to propose a response, state what it costs in the requirement's own units, route it to the person who can accept that cost, and set when the exception expires. Grading that agent needs records of all four steps, not only of what was eventually bought.
Wait, stretch, swap, buy out or redesign: what each response gives up
Disruption responses group into five families: wait for normal supply, stretch what is on hand, use something unqualified or unapproved under a deviation, buy out the remaining supply, or redesign so the item is no longer needed. Each family gives up a different requirement, and a sixth, refurbishing used units, trades away service life.
Two mature programs already catalog these responses. A 2021 article in the Defense Standardization Program Journal lists the nine resolution types in the Defense Department's guidebook for diminishing manufacturing sources and material shortages, SD-22: approved item, life-of-need buy, simple substitute, complex substitute, extension of production or support, repair, refurbishment or reclamation, development of a new item or source, next-higher-assembly redesign, and complex or system-replacement redesign. The program's page says SD-22 was updated in January 2026, so the current edition's list should be checked before relying on that set.
Hospital pharmacy works from the same menu under more time pressure. ASHP's guidelines on managing drug product shortages call for the machinery to exist before a shortage arrives: a shortage team, a resource allocation committee, and set processes for approving alternatives and handling ethical questions. That is a standing statement of who may accept which give-up.
The constraint matrix maps each family to its usual give-up and its risk owner:
| Response family | Requirement usually given up | Who usually accepts the risk | Evidence the acceptance happened |
|---|---|---|---|
| Wait for normal supply | Output or service level during the gap | Operations, or the customer agreeing a new date | Revised promise date and the customer's acknowledgment |
| Stretch on-hand stock (ration, allocate, conserve) | Volume, or even treatment across customers or patients | A resource allocation group, or the planner under a written rule | Rule version in force and each decision made under it |
| Use an unqualified or unapproved item under a deviation | Approval status, labeling or specification conformity | Quality, the customer or a regulator, within a stated scope | Deviation or discretion letter with scope, conditions and end date |
| Buy out remaining supply (life-of-need buy) | Cash, storage and shelf life on stock that may go unused | Finance with the program owner | Approved purchase with quantity rationale and storage plan |
| Redesign or replace the item | Time and requalification risk | Engineering with the product owner | Change order with qualification plan and effective date |
| Refurbish or reclaim used units | Service life or reliability margin | Engineering or maintenance | Inspection criteria and the shortened interval accepted |
Two public deviations, read as decision records
Two FDA actions are public examples of a tradeoff recorded with every part named: the requirement relaxed, the conditions attached, who decided and when the exception ends.
During the 2022 infant formula shortage, FDA guidance issued May 16, 2022 said the agency would consider, case by case, letting formula that is safe and nutritionally adequate into U.S. commerce even if it may not meet every statutory or regulatory requirement, with a label that lists nutrients out of the required order as its example. Manufacturers were asked to send nutrient and ingredient lists, label copies, inventory, microbiological test results and inspection history. The policy ran until November 14, 2022, 182 days after issue. A September 2022 transition plan then extended coverage for products already holding letters to January 6, 2023, day 235, and required a letter of intent to meet all requirements by December 5, 2022; firms without one lost the discretion on January 6, 32 days after that deadline.
The 2023 cisplatin shortage shows a temporary import. FDA's letter to health care providers described cisplatin made in China, not FDA-approved, imported only through Qilu or its distributor Apotex, with Chinese-language vial and carton labels that lacked certain U.S. warning statements; Apotex added a sticker carrying the warning, product name, strength, U.S. NDC, lot and expiration date. In a June 28, 2024 roundup FDA said national supply now exceeded demand, ending the shortage, that it had temporarily declined to enforce importation requirements, and that another approval brought the count of approved manufacturers to seven.
Neither record can show the episode level: which hospital or retailer faced which options, what it rejected, and how its patients or customers fared. That level lives only in the buyer's and supplier's files, and it is what a model has to learn from. Read field by field, the two public records look like this:
| Ledger field | Infant formula, 2022 | Cisplatin, 2023-2024 |
|---|---|---|
| Requirement relaxed | Some statutory or regulatory requirements, case by case | FDA approval and U.S. labeling for an imported product |
| Evidence demanded or control added | Nutrients, ingredients, label, inventory, microbiology, inspection history | Sticker with U.S. warning, name, strength, NDC, lot and expiry; one authorized importer |
| Who accepted the risk | FDA, through product-specific letters | FDA, by not enforcing importation requirements |
| End date or condition | November 14, 2022; then January 6, 2023 without a letter of intent | National supply exceeding demand, announced June 28, 2024 |
| Route back to normal | Letter of intent to meet all requirements by December 5, 2022 | More approved manufacturers; FDA counted seven |
Who accepted the risk, and before or after acting?
The risk owner is whoever holds authority over the requirement being given up, and in a fast disruption that acceptance is often recorded after the action, not before. A dataset that only stores approvals dated before the purchase will mislabel the most common real pattern.
At a glance
Who accepted the risk, and before or after acting
ASHP's guidelines on pharmacy and therapeutics committees say it is not always possible to get approval from committee members before shortage strategies are put in place, and they suggest a standing shortage update on the committee's agenda. In practice, a pharmacist or planner acts under a standing rule and the accountable body ratifies later, or does not. An outside approval also does not settle the inside one: FDA declining to enforce an import requirement leaves each hospital still deciding whether to use the product and under what controls.
Record the timing as a label of its own, because a model that cannot tell these apart will treat silence as consent:
- Pre-authorized: a standing rule named this response and this owner before the disruption.
- Approved before action: the owner signed after the options were laid out and before anything moved.
- Ratified after action: someone acted under urgency and the owner confirmed later, with both dates kept.
- Never ratified: the response happened and no owner ever accepted it.
- Outside authority only: a regulator or customer allowed the relaxation, but no internal owner accepted the operating risk.
The deviation ledger: eleven fields per tradeoff episode
One episode covers one disruption, one affected item and one decision, and the ledger keeps enough to rebuild the choice as it looked that day. Store each field with its source record and timestamp, pseudonymize people and counterparties, and keep the order fixed:
- Disruption: the event, the date it was first known, the affected item, and the expected duration as stated at the time.
- Requirement set: each requirement with its owner and source, such as a specification, approved supplier list, contract term or regulation.
- Options on the decision date: every option considered, with its availability date, quantity and the requirement it would break.
- Options dismissed without analysis, with the reason, so a reviewer can tell a real dead end from a narrow search.
- Choice: the option taken, the quantity and the scope, such as one line, one site or one customer group.
- Give-up: the requirement relaxed and by how much, in its own units: days late, share of demand unmet, a specification value, an approval status.
- Compensating control: added inspection, relabeling, restricted use or closer monitoring.
- Risk acceptance: who accepted, under which authority, the timing label from the previous section, and the dates.
- End: the date or condition at which the deviation lapses, and who reviews it then.
- Reversion: the date normal supply resumed and whether the deviation was closed, renewed or made permanent.
- Outcome: delivered quantities, quality results, complaints and cost variance at fixed horizons after the decision.
Is the cheapest or fastest response ever the right label?
Only when the requirement it breaks is one the accountable owner agreed to give up, for a bounded time, with a control attached. Scoring by speed or cost alone teaches a model to pick whichever option breaks the rule nobody is checking that day.
Two rival explanations need their own tests. First, the perfect alternative may have existed and been missed. Keep the dismissed options field, and have a second reviewer look, for a sample of episodes, for a compliant option that was available on the decision date; episodes where one turns up are search failures, not tradeoffs, and belong in a separate label. Second, a deviation may have quietly become the new normal. Count deviations still open after their end date, and renewals granted without new evidence; FDA's transition plan is a public example of forcing that choice, since firms had to commit to full compliance or lose the exception.
A grader can then score five things separately: did the response name the give-up in its own units, reach the owner with authority over it, attach a control, set an end, and plan the route back. Outcome is scored apart from the decision, because a sound tradeoff can still end badly and a reckless one can get lucky.
Illustrative episode: a pump seal shortage with four imperfect options
Illustrative case, not a real record. A dairy plant's filler pump needs a seal that its approved maker cannot ship for 27 days, and the usable seals on hand cover 6 days of running. Every option breaks something. The gap is the number of days without a seal once the 6 days of cover run out, computed as lead time minus 6 and floored at zero.
The sound decision runs on approved seals for the 6 days they last, orders from the approved alternate supplier at once, and then fits the unapproved equivalent under a deviation signed by the quality manager, with dimensional inspection at receipt and a shortened inspection interval. The deviation ends when the alternate's seals arrive on day 15, and on day 30 at the latest. Refurbishing stays as a fallback. The give-up is approval status for the 9 days between day 6 and day 15, if the alternate ships on time.
A response that switches to the unapproved seal at once and keeps it with no end date gets the speed right, stretches a 9-day give-up into an open-ended one, and fails two of the five scored checks outright: no end and no route back. The options and their costs:
| Option | Lead time, days | Gap after 6 days of cover | Requirement it breaks | Who can accept it |
|---|---|---|---|---|
| Wait for the approved maker | 27 | 21 days | Output: 21 days without the filler | Plant manager with the customer |
| Approved alternate supplier | 15 | 9 days | Output: 9 days without the filler | Plant manager |
| Unapproved equivalent from a distributor | 2 | 0 days | Supplier approval: needs a deviation and inspection | Quality manager |
| Refurbish used seals | 4 | 0 days | Service life: replacement interval halves | Maintenance engineering |
Requesting tradeoff episodes, and where this design stops
Ask for the deviation trail, not the purchase history alone. SourceX does not hold datasets in stock; it finds U.S. businesses that hold the records a buyer describes, and the buyer's request names what it needs, from scope and volume to language, format, deadline and license terms. No records move until the supplying company has approved the scope and terms and signed. For this design the useful records are deviation and concession logs, shortage or allocation committee minutes, allocation rules in force, supplier disruption notices, change orders, and the receipts and quality results that followed. Whether a given company kept them well enough is something only a sample can show.
The limits are plain. The two public cases are U.S. regulatory actions at national level, and the option catalog comes from a 2021 summary of a guidebook revised in January 2026. Not measured: how often real disruption responses carry an end date, how many deviations close on time, or how often a missed compliant option explains an apparent tradeoff. The next evidence needed is one company's deviation records with end dates and reversion entries, enough to count how many closed when they said they would.
Frequently asked questions
What is a supply disruption tradeoff dataset?
It is a set of decision episodes from supply disruptions where every feasible response broke at least one requirement. Each episode records the options open on the decision date, the requirement each would break, the choice, what it gave up, the control added, who accepted the risk, when the exception ends and what happened afterwards.
How is a tradeoff decision different from a supplier substitution?
A substitution decision asks whether a new supplier or part meets the requirement, and the answer can be yes. A tradeoff decision starts after that answer is no for every option, so the record has to show which requirement was relaxed, by whom and for how long.
Who should accept the risk when every option breaks a requirement?
The person or body with authority over the requirement being relaxed: quality for approval status, the customer for a delivery date, a regulator for a legal requirement. Hospital guidance from ASHP notes that approval sometimes comes after urgent action, so record both the action date and the acceptance date.
Why record the options that were rejected?
Without them, nobody can tell a genuine tradeoff from a search that missed a compliant option. Rejected options, with their availability dates and the rule each broke, let a reviewer test the decision and let a model learn the comparison, not just the result.
How long should a disruption deviation last?
Set an end date or end condition when the deviation is granted, and name who reviews it then. FDA's 2022 infant formula policy carried an end date from its first day and later required firms to commit to full compliance or lose the exception.
Sources
- A 2021 Defense Standardization Program Journal article lists the nine DMSMS resolution types in SD-22, from approved item and life-of-need buy to system-replacement redesign. Source
- DLA's DMSMS program page says the SD-22 guidebook was updated in January 2026. Source
- FDA's May 16, 2022 guidance set case-by-case enforcement discretion for safe, nutritionally adequate infant formula that may not meet every requirement, listed the information firms had to send, and ran to November 14, 2022. Source
- FDA's September 2022 transition plan extended discretion for lettered products to January 6, 2023 and required a letter of intent to comply by December 5, 2022. Source
- FDA's 2023 letter on temporarily imported cisplatin describes an unapproved product from China, its authorized importer and distributor, its labeling differences and the added sticker. Source
- FDA's June 28, 2024 roundup says cisplatin supply exceeded demand, ending the shortage, notes the temporary importation discretion and counts seven approved manufacturers. Source
- ASHP's guidelines on managing drug product shortages call for a shortage team, a resource allocation committee and processes for approving alternatives before a shortage occurs. Source
- ASHP's P&T committee guidelines say approval from committee members is not always possible before shortage strategies are implemented and suggest a standing shortage update. Source
Tell us what data you need
Share scope, volume, format, timing and licensing needs. Datasets are sourced on request.